Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin

Circulation: Heart Failure

Volumn 11, Issue 2, 2018, Pages

  Hanson, Jacquelyn L S ^a   Arvanitis, Marios ^a   Koch, Clarissa M ^a,b   Berk, John L ^a   Ruberg, Frederick L ^a   Prokaeva, Tatiana ^a   Connors, Lawreen H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Amyloid; Biomarker; Heart failure; Risk factor; Survival

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; DIFLUNISAL; TRANSTHYRETIN; TROPONIN I; URIC ACID;

ADULT; AGED; ARTICLE; ATTR AMYLOIDOSIS; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SEDIMENTATION RATE; SHORT TERM SURVIVAL; SURVIVAL FACTOR; SURVIVAL PREDICTION; BLOOD; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; VENTRICULAR FUNCTION, LEFT;

EID: 85052304933     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.004000     Document Type: Article

References (31)

1. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004;255:159–178.
2. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12:91–102. doi: 10.1038/ nrcardio.2014.165.
3. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203–1212. doi: 10.1161/CIRCULATIONAHA.108.843334.
4. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA. 1990;87:2843–2845.
5. Mita S, Maeda S, Shimada K, Araki S. Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. J Biochem. 1986;100:1215–1222.
6. Rostom AA, Sunde M, Richardson SJ, Schreiber G, Jarvis S, Bateman R, Dobson CM, Robinson CV. Dissection of multi-protein complexes using mass spectrometry: subunit interactions in transthyretin and retinol-binding protein complexes. Proteins. 1998;33(suppl 2):3–11.
7. Ritchie, R. Serum proteins in clinical medicine. In: Ritchie R, ed. vol 1. Scarborough, ME: AACC, Foundation for Blood Research; 1996:9.01–9.06.
8. Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid. 2008;15:255–261. doi: 10.1080/13506120802525285.
9. Myron Johnson A, Merlini G, Sheldon J, Ichihara K; Scientific Division Committee on Plasma Proteins (C-PP), International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med. 2007;45:419–426. doi: 10.1515/ CCLM.2007.051.
10. Oppehneimer JH, Surks MI, Bernstein G, Smity JC. Metabolism of iodine-131–labeled thyroxine-binding prealbumin in man. Science. 1965;149:748–750.
11. Buxbaum J, Anan I, Suhr O. Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid. 2010;17:83–85. doi: 10.3109/13506129.2010.483118.
12. Skinner M, Connors LH, Rubinow A, Libbey C, Sipe JD, Cohen AS. Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives. Am J Med Sci. 1985;289:17–21.
13. Connors LH, Gertz MA, Skinner M, Cohen AS. Nephelometric measurement of human serum prealbumin and correlation with acute-phase proteins CRP and SAA: results in familial amyloid polyneuropathy. J Lab Clin Med. 1984;104:538–545.
14. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425–1429. doi: 10.1001/ archinte.165.12.1425.
15. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282–290. doi: 10.1161/ CIRCULATIONAHA.115.018852.
16. Sawyer DB, Skinner M. Cardiac amyloidosis: shifting our impressions to hopeful. Curr Heart Fail Rep. 2006;3:64–71.
17. Falk RH. Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques? Amyloid. 2012;19(suppl 1):68–70. doi: 10.3109/13506129.2012.674074.
18. Liu PP, Smyth D. Wild-type transthyretin amyloid cardiomyopathy: a missed cause of heart failure with preserved ejection fraction with evolving treatment implications. Circulation. 2016;133:245–247. doi: 10.1161/ CIRCULATIONAHA.115.020351.
19. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020. doi: 10.1016/j.jacc.2016.06.033.
20. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, Salvi F, Maurer MS. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20:117–124. doi: 10.1007/s10741-015-9480-0.
21. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129:1840–1849. doi: 10.1161/CIRCULATIONAHA.113.006242.
22. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60:765–774. doi: 10.1111/j.1532-5415.2011.03868.x.
23. Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the reemergence of nuclear cardiology. Am J Med. 2015;128:1275–1280. doi: 10.1016/j.amjmed.2015.05.039.
24. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–2466. doi: 10.1016/j.jacc.2015.09.075.
25. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of am-yloidogenesis. J Med Chem. 2004;47:355–374. doi: 10.1021/jm030347n.
26. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667. doi: 10.1001/jama.2013.283815.
27. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R. Ta-famidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629–9634. doi: 10.1073/pnas.1121005109.
28. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56: 337–344.
29. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76. doi: 10.1185/03007995.2012.754348.
30. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilb-ertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:e000098. doi: 10.1161/JAHA.113.000098.
31. Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model. JAMA Cardiol. 2017;2:305–313. doi: 10.1001/jamacardio.2016.5864.